Safety Information on Varubi (Rolapitant) Injectable Emulsion
Jan 15
2018
The Oncology Center of Excellence of the U.S. Food and Drug Administration is informing health care providers about new safety information for Varubi® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.
